SCHEMBL13628107

SCHEMBL13628107

COC(=O)c1cccc(CN2C(=O)/C(=N/O)c3ccc(-c4ccc5ccccc5c4)cc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.50
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
MAPT P10636 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GSK3B P49841 1/20 0.42
PLAU P00749 2/20 0.42
TNIK Q9UKE5 1/20 0.42
TP53 P04637 1/20 0.41
IDO1 P14902 1/20 0.41
POLB P06746 2/20 0.41
TGM2 P21980 1/20 0.40
CD74 P04233 1/20 0.40
MIF P14174 1/20 0.40
MAPK10 P53779 1/20 0.40
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628102 0.89 TRPA1 (0.48) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628096 0.86 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628116 0.85 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628131 0.84 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13910829 0.84 TRPA1 (0.47) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13910942 0.83 TRPA1 (0.51) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628123 0.83 TRPA1 (0.51) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13637451 0.78 TRPA1 (0.45) TRPA1ROCK2ROCK1MAPTL3MBTL1
SCHEMBL13628109 0.77 CCNC (0.41) MAPTPOLBMAPK1HSD17B10SLC6A2
SCHEMBL1164954 0.73 KMT2A (0.70) TRPA1MAPTL3MBTL1GSK3BTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 TRPA1 4561/4885ROCK2 246/4885ROCK1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.